Overview
FemEase, developed by Susan, is an innovative Class II medical device designed as a mechanical solution to support urinary management and reduce associated risks such as irritation and infection. With support from Go Vertical ICM , Susan is defining the regulatory and validation strategy while preparing for a potential FDA submission under the 510(k) pathway. Although the device has not yet been submitted to the FDA, significant steps have been taken toward supporting clinical validation and regulatory alignment
Phase 1: Initial Development and Preclinical Testing
Susan’s vision for FemEase was to create a device that addressed the discomfort commonly associated with urinary management solutions. She collaborated with Go Vertical ICM to refine the initial concept and ensure that the device met medical-grade safety standards while providing a superior user experience.
During the preclinical phase, the product underwent extensive testing to assess its functionality, safety, and material compatibility for long-term medical use. These early tests were critical for identifying any design issues before entering human trials.
Key Actions:
• Preclinical Testing: Focused on evaluating the materials and mechanical performance of FemEase to ensure that it met medical standards.
• Design Adjustments: Changes were made to the design based on feedback from preclinical tests to improve usability and durability.
Phase 2: Preparing for Clinical Trials
If FemEase is intended to claim a reduction in UTIs, clinical evidence will be required to support that claim. Clinical studies are particularly important for medical devices used in sensitive applications involving urinary management, where both patient comfort and functionality are critical.
Go Vertical ICM assisted Susan in developing the clinical trial protocol and securing partnerships with experienced clinical research organizations (CROs) to conduct the trials.
The validation approach includes feasibility and usability assessments, with clinical studies required to support specific outcome claims such as UTI reduction.
Key Actions:
• Clinical Protocol Development: Go Vertical ICM worked closely with Susan to develop a comprehensive clinical trial protocol that would meet FDA standards.
• Partnering with CROs: The team partnered with clinical experts to ensure that the trials were conducted according to regulatory requirements and best practices in medical research.
Phase 3: Preparing for FDA Submission
Although FemEase has not yet been submitted to the FDA, the preparation for 510(k) clearance is already underway. This pathway requires demonstrating that FemEase is substantially equivalent to another legally marketed device (a predicate), while also outlining its intended use and design characteristics.
Go Vertical ICM is assisting Susan with the compilation of the required data and documentation for submission. This includes:
• Validation Data: Supporting evidence from bench testing and usability studies, with clinical data required to substantiate outcome-based claims such as UTI reduction
• Technical Documentation: Detailed information on the device’s design, function, and manufacturing processes.
• Risk Assessment: Identifying potential risks associated with the device and providing strategies for mitigating those risks.
Key Actions:
• Preliminary Documentation: Preparation of 510(k) materials, ensuring all validation data and design details are appropriately documented in line with the regulatory strategy
• Regulatory Strategy: Working with Susan to create a roadmap for submission, addressing all key regulatory requirements.
Phase 4: Market Preparation and Supply Chain Strategy
As the regulatory strategy is being defined, Go Vertical ICM is also helping Susan prepare for the market launch of FemEase. This includes establishing a robust supply chain and distribution strategy, as well as creating educational materials for healthcare providers who will be key in adopting the product.
• Supply Chain Management: Ensuring that the materials and components required to manufacture FemEase are readily available and can be scaled up as needed.
• Distribution Planning: Identifying potential distribution partners in the healthcare sector to bring FemEase to hospitals and clinics.
• Marketing and Awareness: Developing campaigns aimed at educating healthcare providers and patients about the benefits of FemEase.
Key Actions:
• Supply Chain Setup: Ensuring that manufacturing can scale efficiently once FDA approval is secured.
• Healthcare Provider Engagement: Preparing marketing strategies to introduce FemEase to key decision-makers in the healthcare sector.
Key Takeaways:
1. Thorough Preclinical Testing: Early testing ensured that the materials and design of FemEase were safe and effective, setting the stage for successful clinical trials.
2. Clinical Trial Preparation:
Clinical studies are required when making outcome-based claims such as reduction of UTIs. Partnering with experienced clinical research organizations (CROs) is critical.
3. Regulatory Readiness: Although FemEase has not yet been submitted to the FDA, Go Vertical ICM is supporting the preparation of documentation required for a 510(k) submission.
4. Market Launch Planning: Preparing for supply chain scalability and engaging healthcare providers early ensures that FemEase will be ready to hit the market once regulatory approval is granted.
With Go Vertical ICM support, Susan is well-positioned to bring FemEase to market, advancing solutions in urinary management and patient comfort and providing a new, patient-friendly option for women in need of this type of solution. As with similar devices, clinical studies are required when making outcome-based claims such as reduction of UTIs.
